Ceruso Francesco Mattia, Lumbau Aurea Immacolata, Pernice Francesco, Mastroianni Alessandro, Miranda Michele, Meloni Silvio Mario, Gargari Marco, Tallarico Marco, Pisano Milena
Department of Dentistry "Fra G.B. Orsenigo-Ospedale San Pietro F.B.F.", 00100 Rome, Italy.
Department of Medicine, Surgery, and Pharmacy, University of Sassari, 07100 Sassari, Italy.
Dent J (Basel). 2025 Apr 28;13(5):193. doi: 10.3390/dj13050193.
: This retrospective study aimed to evaluate the increase in vertical bone height following sinus lift procedures using the CAS (Crestal Approach Sinus) kit technique in combination with tissue-level implants. Additionally, the quantity of bone between the implant apex and the Schneiderian membrane was assessed to determine the effectiveness and safety of this minimally invasive approach. : The study included 15 patients (20 implants) who underwent sinus lift procedures with the CAS kit technique and tissue-level implants in the posterior maxilla between September 2021 and October 2024. Inclusion criteria required a minimum residual bone height (RBH) of 2 mm. Cone-beam computed tomography (CBCT) scans were used for initial screening, and panoramic radiography evaluated outcomes at implant placement and nine months postoperatively. Primary outcomes included implant and prosthetic survival rates, as well as biological and technical complications. Secondary outcomes were vertical bone height and the amount of bone above the implant tip. Statistical analyses were conducted using the Wilcoxon signed-rank test with a significance level of 0.05. : All implants achieved successful osseointegration, with no implant or prosthetic failures and no biological or technical complications reported. The mean RBH at implant placement was 4.2 ± 1.4 mm, which increased to an overall membrane elevation of 13.8 ± 1.8 mm. At the 9-month follow-up, the overall membrane elevation was slightly reduced to 13.0 ± 1.6 mm ( = 0.000), with a mean bone gain of 9.6 ± 2.4 mm. The amount of bone above the implant tip was 3.4 ± 1.7 mm at placement, decreasing to 3.0 ± 1.2 mm at follow-up ( = 0.007). : The CAS kit technique combined with tissue-level implants demonstrated significant vertical bone gain and high implant survival rates without complications. This minimally invasive approach proved effective and safe for sinus augmentation in patients with limited residual bone height. The findings support the CAS kit's potential as a preferred technique for maxillary sinus elevation. Further research with larger cohorts and long-term follow-up is needed to validate these results.
本回顾性研究旨在评估使用CAS(嵴顶入路鼻窦)套件技术联合组织水平种植体进行鼻窦提升术后垂直骨高度的增加情况。此外,评估种植体顶端与施奈德膜之间的骨量,以确定这种微创方法的有效性和安全性。
该研究纳入了2021年9月至2024年10月期间在双侧上颌后牙区接受CAS套件技术联合组织水平种植体鼻窦提升术的15例患者(20枚种植体)。纳入标准要求最小剩余骨高度(RBH)为2mm。锥形束计算机断层扫描(CBCT)用于初始筛查,全景X线片评估种植体植入时及术后9个月的结果。主要结局包括种植体和修复体生存率以及生物学和技术并发症。次要结局为垂直骨高度和种植体顶端上方的骨量。采用Wilcoxon符号秩检验进行统计分析,显著性水平为0.05。
所有种植体均实现了成功的骨整合,未报告种植体或修复体失败以及生物学或技术并发症。种植体植入时的平均RBH为4.2±1.4mm,整体膜提升至13.8±1.8mm。在9个月的随访中,整体膜提升略有下降至13.0±1.6mm(P=0.000),平均骨增量为9.6±2.4mm。种植体顶端上方的骨量在植入时为3.4±1.7mm,随访时降至3.0±1.2mm(P=0.007)。
CAS套件技术联合组织水平种植体显示出显著的垂直骨增量和高种植体生存率,且无并发症。这种微创方法对剩余骨高度有限的患者进行鼻窦增量有效且安全。研究结果支持CAS套件作为上颌窦提升首选技术的潜力。需要进一步开展更大样本量和长期随访的研究来验证这些结果。